Brokerage firm Stifel Nicolaus Maintains its rating on NewLink Genetics Corp(NASDAQ:NLNK). In a research note issued to the investors, the brokerage major Lowers the price-target to $22.00 per share. The shares have been rated Buy. The rating by Stifel Nicolaus was issued on Aug 1, 2016.
In a different note, On May 11, 2016, SunTrust Robinson Humphrey said it Downgrades its rating on NewLink Genetics Corp. The shares have been rated ‘Neutral’ by the firm.
NewLink Genetics Corp (NLNK) shares turned negative on Mondays trading session with the shares closing down -0.32 points or -2.91% at a volume of 2,13,388. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $11.16. The peak price level was also seen at $11.16 while the days lowest was $10.61. Finally the shares closed at $10.68. The 52-week high of the shares is $56.16 while the 52-week low is $9.23. According to the latest information available, the market cap of the company is $309 M.
NewLink Genetics Corp(NLNK) last announced its earnings results on Jul 29, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.01M. Analysts had an estimated revenue of $5.41M. Earnings per share were $-1.12. Analysts had estimated an EPS of $-0.81.
Several Insider Transactions has been reported to the SEC. On Jun 8, 2016, Ernest Iii Talarico (director) purchased 4,065 shares at $12.32 per share price.Also, On Apr 11, 2016, Charles J. Jr. Link (Chairman of the Board and CEO) sold 10,000 shares at $20.02 per share price.On Jan 6, 2016, Brian Wiley (VP of Business Development) sold 1,295 shares at $34.73 per share price, according to the Form-4 filing with the securities and exchange commission.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system’s tolerance to cancer by inhibiting the indoleamine-(2 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.